Company: NCEL
Filing Date: 2025-06-09
Form Type: F-4/A
Source: 0001213900-25-052354
Chunk: 144

Company: NewcelX Ltd.
Filing Date: 2025-06-09
Form: F-4/A
Chunk 144
---
 industry may be enacted in the future or what effect recently enacted federal legislation or any such additional legislation or regulation would have on its business. The pendency or approval of such proposals or reforms could result in a decrease in the price of its NLS Common Shares or Warrants or limit its ability to raise capital or to enter into collaboration agreements for the further development and potential commercialization of its products. The use of any of NLS’s product candidates could result in product liability or similar claims that could be expensive, damage its reputation and harm its business. NLS’s business exposes it to an inherent risk of potential product liability or similar claims. The pharmaceutical industry has historically been litigious, and NLS face financial exposure to product liability or similar claims if the use of any of its products were to cause or contribute to injury or death. There is also the possibility that defects in the design or manufacture of any of its products might necessitate a product recall. Although NLS plan to maintain product liability insurance, the coverage limits of these policies may not be adequate to cover future claims. In the future, NLS may be unable to maintain product liability insurance on acceptable terms or at reasonable costs and such insurance may not provide it with adequate coverage against potential liabilities. A product liability claim, regardless of merit or ultimate outcome, or any product recall could result in substantial costs to us, damage to its reputation, customer dissatisfaction and frustration and a substantial diversion of management attention. A successful claim brought against it in excess of, or outside of, its insurance coverage could have a material adverse effect on its business, financial condition and results of operations. NLS Risks Related to the Ownership of its Securities The market price of NLS Common Shares and Warrants may be highly volatile, and you may not be able to resell your shares or Warrants at or above the initial public offering price. The trading price of each of NLS Common Shares and Warrants is likely to be volatile. The following factors, in addition to other risk factors described in this section, may have a significant impact on the market price of such securities: •unsatisfactory results of clinical trials; •announcements of regulatory approval or the failure to obtain it, or specific label indications or patient populations for its use, or changes or delays in the regulatory review process; •announcements of therapeutic innovations or new products by NLS or its competitors; •adverse actions taken by regulatory authorities with respect to NLS’s clinical trials, manufacturing supply chain or sales and marketing activities; •changes or developments